Wegovy before and after: what women typically experience

Six months in: why the early weeks feel different from what you expected

Imagine it's a Tuesday evening. You've had your first pen in the fridge since Saturday, you've read the patient leaflet twice, and you're genuinely unsure whether what you're feeling is the medicine or your own nerves. That's a common starting point. The first four weeks of Wegovy use the 0.25mg dose, which is a tolerability step — its job is to let your system adjust, not to produce measurable weight loss yet. Many women report that nausea is most noticeable here, usually peaking on the day after injection and easing within a few days.

By weeks 5 to 8, the dose moves to 0.5mg and most women begin to notice appetite genuinely falling. Not through willpower, through a quieting of the hunger signals the brain normally sends. This is when the first scale changes tend to appear. The timeline for Wegovy to produce visible results varies between individuals, but the pattern in trial data is consistent: slow and steady in the opening months, accelerating through the middle of the first year. Women often describe this phase as the one where clothes start to feel different before the number on the scale moves dramatically.

By month four or five, many women are on the 1.7mg dose and the cumulative effect becomes more visible to others. The gastrointestinal side effects that were present early (nausea, occasional constipation, a change in digestion) typically settle well before this point for most people. The NHS semaglutide medicines page has a clear, readable summary of what to expect at each stage and when to contact a prescriber.

What women in the STEP 1 trial actually lost, and what the average hides

The headline figure from STEP 1 is around 15% average weight loss at 68 weeks. For a woman starting at 100kg, that is 15kg. For someone starting at 85kg, it is around 13kg. But averages obscure spread: roughly one third of participants lost more than 20% of their body weight, while others lost considerably less. Understanding that range matters, because Wegovy's results before and after depend heavily on adherence to treatment, diet quality, activity levels, and individual metabolic factors.

The trial enrolled adults with obesity or overweight with at least one weight-related condition, alongside a structured lifestyle programme. Women without type 2 diabetes made up the majority of participants. Side effects were more commonly reported in women than men in some analyses, particularly nausea in the early weeks, but treatment discontinuation rates due to side effects were low overall. The consistent message from the data is that the women who stayed on treatment longest, and who reached the 2.4mg maintenance dose, saw the largest changes. Stopping early (whether because of side effects, cost, or inconvenience) shortens that arc considerably.

With the new 7.2mg dose approved by the MHRA in early 2026, trials reported average weight loss approaching 20.7% over 72 weeks, narrowing the gap with tirzepatide. For women considering their options, understanding the full weight-loss trajectory on Wegovy is a reasonable starting point for that conversation with a prescriber.

What changes beyond the scale, and what stays the same

Women who complete the first year of treatment consistently report changes that go beyond a lower number on the scales. Reduced joint discomfort from carrying less weight, improved energy in the second half of the day, better sleep in those with sleep apnoea, and a different relationship with food, specifically, the absence of the near-constant low-level preoccupation with eating that many describe as exhausting. These are not guaranteed outcomes; they are patterns from Wegovy before and after accounts that align with what trial data captures in quality-of-life measures.

What does not automatically change: muscle mass, if resistance exercise is not part of the picture. Wegovy reduces appetite broadly, which can mean total protein intake drops. Preserving lean mass matters both for how the body looks after weight loss and for longer-term metabolic health. A prescriber can discuss this as part of ongoing care. For women curious about how physical changes tend to present over time, before and after Wegovy pictures from female patients illustrate the range of outcomes documented across different starting points and timescales. For women curious about how male physiology compares in terms of pace and pattern of change, the Wegovy before and after experience for men covers the documented differences.

Finally, what the photographs shared online rarely show: the dose titration period, the weeks of patience when the scale barely moves, the meal where nausea wins. The changes women experience on Wegovy are real and often substantial. They are also gradual, biological, and require a clinician alongside you. If you are weighing whether semaglutide is the right fit, exploring your weight-loss treatment options with a prescriber is a more useful step than any before-and-after photograph.